Lloyd G. Tillman, Ph.D., Executive Director of Pharmaceutical Development, ISIS Pharmaceuticals, Inc.
Lloyd G. Tillman, Executive Director of Pharmaceutical Development, ISIS Pharmaceuticals, Inc.
Dr. Lloyd Tillman is Executive Director of Pharmaceutical Development at Isis Pharmaceuticals, Inc., Carlsbad, CA.
is responsible for formulation research and development of antisense drugs.
Beyond enabling new formulations for antisense based therapeutics, he manages development activities for preclinical and clinical supplies and for product registration.
While at Isis
has published several peer-reviewed manuscripts focusing on oligonucleotide formulations.
also lectures courses on Drug Dosage Form Design and Delivery Systems and on Concepts of Pharmacy Practice at the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences
Prior to joining Isis in 1997, Dr. Tillman worked at the FDA overseeing the Product Quality Research Laboratory within CDER.
group focused to derive science-based data to support SUPAC and Biopharmaceutics Drug Classification System initiatives and other regulatory guidance's.
Previous to the FDA he worked on oral solid dosage forms at Burroughs Wellcome Co. where he managed the pharmaceutical product development of several NCE's into clinical trials and in two cases (MEPRON and VALTREX) into production and onto the market.